Market Newsdesk

• Patient screening and dosing ongoing in Turkey and Hungary
  
• Topline data expected in Q2 2021 for the Combination Trial

DELRAY BEACH, Fla., Nov. 30, 2020 (GLOBE NEWSWIRE) — AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that the first two patients have been dosed in Turkey for its Phase 2 trial evaluating its investigational drug, MS1819, in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy (PERT), for the treatment of severe exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF).

“In the midst of a global pandemic and unpredictable obstacles, we are very encouraged to see our Combination therapy trial moving forward at one of the clinical testing sites in Turkey,” said James Sapirstein, President & CEO of AzurRx.  Mr. Sapirstein continued, “We expect to release topline results in the second quarter of next year. We are optimistic the results will build on the encouraging data we received earlier this year and hope we will be one step closer to improving the lives of thousands of patients suffering from cystic fibrosis.”

Earlier last month, the Company reported that additional clinical sites were activated in Turkey, which follows Hungary as the second country where patients have been screened and dosed in the Combination trial.  As of today, there are five sites activated in Turkey that are currently screening for patients.

The Phase 2 Combination Trial, open-label, multicenter study is assessing the safety and efficacy of MS1819 administered over 15 days in immediate release capsules in increasing doses of 700mg, 1,200mg and 2,240 mg per day, in combination with a patient’s daily dose of PERT.  Previously reported results on the initial five patients in the trial revealed that the combination therapy led to clinically meaningful improvements in the primary efficacy endpoint, the coefficient of fat absorption (CFA), and improvements in the key secondary endpoints, including body weight, stool consistency and reductions in the number of bowel movements and the incidence of steatorrhea (excessive amounts of fat in the feces).

About the MS1819 Combination Therapy Trial

The digestive standard of care for both CF and chronic pancreatitis (CP) patients with EPI are commercially-available PERTs. Ideally, a stable daily dose of PERT will enable CF patients to eat a normal to high-fat diet and minimize unpleasant gastrointestinal symptoms. In practice, however, a substantial number of CF patients do not achieve normal absorption of fat with PERTs^(1,2).  Achieving an optimal nutritional status, including normal fat absorption levels, in CF patients is important for maintaining better pulmonary function, physical performance and prolonging survival. Furthermore, a decline of body mass index around the age of 18 years predicts a substantial drop in lung function^(3,4).

A combination therapy of PERT and MS1819 has the potential to: (i) correct macronutrient and micronutrient maldigestion; (ii) eliminate abdominal symptoms attributable to maldigestion; and (iii) sustain optimal nutritional status on a normal diet in CF patients with severe EPI. Planned enrollment is expected to include approximately 24 CF patients with severe EPI, with study completion anticipated in Q2 2021.

About MS1819

MS1819 is a recombinant lipase enzyme for the treatment of exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis. MS1819, supplied as an oral non-systemic biologic capsule, is derived from the Yarrowia lipolytica yeast lipase and breaks up fat molecules in the digestive tract of EPI patients so that they can be absorbed as nutrients. Unlike the standard of care, the MS1819 synthetic lipase does not contain any animal products.

About AzurRx BioPharma, Inc.

AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a biopharmaceutical company specialized in the research and development of non-systemic biologics for gastrointestinal disorders. The Company is focused on the development of its lead drug candidate, MS1819. AzurRx is currently conducting two Phase 2 clinical trials of MS1819: the OPTION 2 monotherapy trial, and the Combination therapy trial, consisting of MS1819 in conjunction with porcine-derived pancreatic enzyme replacement therapy, the current standard of care. The Company is headquartered in Delray Beach, Florida with clinical operations in Hayward, California. Additional information on the Company can be found at www.azurrx.com.

Forward-Looking Statements

This press release may contain certain statements relating to future results which are forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, including whether results obtained in preclinical and nonclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether preliminary or interim results from a clinical trial such as the interim results presented will be indicative of the final results of the trial. Additional information concerning the Company and its business, including a discussion of factors that could materially affect the Company’s financial results, including those related to the clinical development of MS1819, the results of its clinical trials, and the impact of the coronavirus (COVID-19) pandemic on the Company’s operations and current and planned clinical trials, including, but not limited to delays in clinical trial recruitment and participation are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 under the heading “Risk Factors,” as well as the Company’s subsequent filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

For more information:

AzurRx BioPharma, Inc.
1615 South Congress Avenue
Suite 103
Delray Beach, Florida 33445
Phone: (646)-699-7855
[email protected]

Investor Relations contact:

LifeSci Advisors, LLC. 
Hans Vitzthum, Managing Director 
1 International Place, Suite 1480 
Boston, MA 02110 
Phone: 617-430-7578 
[email protected]

References

(1) Freedman, S.D., Am. J. Manag. Care, 2017; 23: S2220-S228
(2) Littlewood, J. et al, 2006, Pediatric Pulmonology, 2006, 41:35-49
(3) Engelen, M. et al, 2014, Curr. Opin. Clin. Nutr. Metab. Care; 17(6):515-520
(4) Vandenbranden, S.L. et al, 2012, Pediatric Pulmonology, 2012; 47(2): 135-143

• The ERJ Paper shows major effects on biomarkers in IPF, linked to mortality and to fall in FVC
• The inhaled GB0139 significantly reduced key plasma biomarkers from baseline vs placebo over 2 weeks
• GB0139 is being investigated in the 450 patients, 52 week GALACTIC-1 Phase 2b/3 trial in IPF

BOSTON and COPENHAGEN, Denmark, Nov. 30, 2020 (GLOBE NEWSWIRE) — Galecto, Inc., a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced today the publication of a paper detailing full results from a phase 2a study of GB0139 in Idiopathic Pulmonary Fibrosis (IPF) in the peer-reviewed publication European Respiratory Journal.

The study highlights the effect of inhaled GB0139 in IPF patients on the plasma levels of highly relevant disease biomarkers, in particular YKL-40 and CCL-18, which have been shown to have prognostic significance in IPF (YKL-40 linked to IPF mortality and CCL-18 linked to fall in lung function – FVC). These and several other biomarkers (PDGF-B, PAI-1, Galectin-3) were reduced in a dose dependent fashion from baseline in a consistent and statistically significant manner, with the strongest effects in the 10 mg dose group compared to placebo.

Hans Schambye, CEO of Galecto, said: “We are excited that the study showed that with intervention with our inhaled small molecule therapy GB0139 in the lungs of IPF patients, we see fast onset and major reduction in a series of biomarkers known as drivers of lung fibrosis and linked to IPF mortality. GB0139’s concerted and marked impact on these biomarkers support its potential to make a significant difference in the treatment of IPF, and we are looking forward to advancing it further through clinical development and potentially to market.”

GB0139, an inhaled small molecule inhibitor of galectin-3, a protein known to play a central role in fibrosis in several organs, has received Orphan Drug Designation (ODD) from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of IPF. The EMA cited clinically relevant biomarker data, in particular the significant reduction of YKL-40 in IPF patients, as a justification for the ODD designation. GB0139 was shown to be safe and well tolerated in healthy subjects and IPF patients in the phase 2a trial, and dose dependently suppressed expression of galectin-3, a protein known to play a central role in fibrosis in several organs, on alveolar macrophages.

“The availability of multiple biomarkers of IPF pathogenesis means physicians can not only monitor the progression of disease but also differentiate the effects of different treatments. The lockstep reduction in five biomarkers – PDGF-BB, PAI-1, Galectin-3, CCL18 and YKL-40 – in patients treated with TD139, but not with placebo, is an encouraging early sign that will require clinical confirmation,” said Toby Maher, one of the authors of the paper and Professor at Royal Brompton Hospital, Imperial College London and University of Southern California.

Galecto is now investigating GB0139 (formerly TD139) in the Phase 2b/3 GALACTIC-1 clinical trial in IPF. The trial is a pivotal size, randomized, double-blind, multicenter, parallel, placebo-controlled study across more than 100 centers in the U.S., the EU, and Canada, designed to evaluate the efficacy and safety of GB0139 in 450 subjects with IPF over 52 weeks.

About Galecto

Galecto is a clinical stage biotechnology company with advanced programs in fibrosis and cancer centered on galectin-3 and LOXL2. The company’s pipeline includes an inhaled galectin-3 modulator currently in phase 2b for the potential treatment of idiopathic pulmonary fibrosis, as well as two assets about to move into phase 2 targeting myelofibrosis, NASH and oncology. The Company is incorporated in the U.S. and has its operating headquarters in Copenhagen, Denmark.

Further information can be found at www.galecto.com.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Galecto’s focus, GB0139’s potential, plans for clinical development and potential to market, and Galecto’s product candidates and pipeline. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. For such statements, Galecto claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Galecto’s expectations. Factors that could cause actual results to differ materially from the forward-looking statements include risks and uncertainties related to the development of Galecto’s product candidates and their therapeutic potential, having adequate funds and their use, and those disclosed in Galecto’s filings with the Securities and Exchange Commission, including its Registration Statement on Form S-1. These forward-looking statements represent Galecto’s judgment as of the time of this release. Galecto disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
For more information, contact:

Galecto Inc.	LifeSci Advisors (media)
Hans Schambye, CEO Jon Freve	Mary-Ann Chang
+45 70 70 52 10	+44 7483 284 853
[email protected]	[email protected]

FOSTER CITY, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) — GridGain^® Systems, provider of enterprise-grade in-memory computing solutions based on Apache^® Ignite^®, today announced it is hosting or participating in multiple online conferences, webinars and virtual meetups taking place in December and January 2020. GridGain will use these events to share unique insights into the latest in-memory computing technology developments, trends and strategies. GridGain has also posted on-demand videos of multiple November 2020 events on the company’s website.

“We have seen soaring interest in our events over the last few months as more companies of every size look to push their digital transformations forward,” said Terry Erisman, Executive Vice President of Corporate Development at GridGain Systems. “Our team of experts is always excited to share their wealth of information about how in-memory computing can support highly performant, massively scalable applications and enable vital new infrastructure strategies, such as digital integration hubs and HTAP.”

Webinars

• 
  How to Deploy Change Data Capture Using Debezium in Apache Ignite and GridGain
  
  – December 2, 2020 – Evgenii Zhuravlev, GridGain Customer Solutions Team Lead, will explain how Kafka with Debezium and GridGain connectors enables change data capture (CDC)-based synchronization between third-party databases and GridGain clusters. Webinar attendees will learn how to deploy such an architecture by configuring a Debezium Connector and a GridGain Certified Kafka Connector.

• 
  Apache Ignite Workshop: Developing Applications That Are Easy to Manage
  
  – 
  December 9, 2020 – Alexey Kukushkin, GridGain Professional Services Consultant, will discuss how to develop applications that are easy to manage, including the various methods for using Apache Ignite to develop manageable applications and the monitoring and managing tools that Apache Ignite provides.

• 
  Learn How Our Managed Services Offering Deploys GridGain and Apache Ignite in the Cloud
  
  – January 13, 2021 – Andrey Alexandrov, GridGain Senior Software Engineer, will guide attendees through the internal workings of GridGain Nebula, a managed services offering for Apache Ignite and GridGain. The session will provide a brief overview of the solution’s technology stack and architecture and live examples of how to use GridGain Nebula to accelerate platform deployment and configuration in public clouds.

• 
  Distributed Application Development Training: Approaches for User Authentication
  
  – On Demand – Denis Mekhanikov, GridGain Client Service Lead, reviews the various approaches to storing and using authentication data in distributed applications. Moving from the simplest to the most complex models, Mekhanikov outlines the pros and cons of each approach, and gives special attention to one of the most popular approaches to distributed sessions—single sign-on.

• 
  How to Leverage the Grid
  
  
  G
  
  
  ain Operator for Kubernetes to Deploy Apache Ignite
  
  – On Demand – Alexander Shapkin, GridGain Software Engineer, demonstrates the difference between in-memory clusters and persistent clusters, how to move step by step through the configuration, and how to use The GridGain Operator for Kubernetes to deploy Apache Ignite in AWS. 

Virtual


Meetups

• 
  In-Memory Computing Essentials for Java Developers and Architects with Java.IL
  
  –
  November 30, 2020 – Denis Magda, GridGain Vice President of Developer Relations in R&D and Apache Ignite Committer and PMC Member, will introduce the fundamental capabilities of distributed, in-memory systems and will demonstrate how to tap into a cluster’s resources and how to negate any negative impact that the network might have on the performance of applications.

• 
  Apache Ignite Talks
  
  – December 8, 2020 – Ken Cottrell, GridGain Solution Architect and Mikhail Antonov, platform owner of the core banking system at Raiffeisen Bank, Russia, will co-host a meetup for the Apache Ignite community to learn more about how Apache Ignite is used for Raiffeisen Bank’s backend and how to work with Ignite compute grid and Drool. 

Conferences

• 
  jLove
  
  – December 4, 2020 – Denis Magda, GridGain Vice President of Developer Relations in R&D and Apache Ignite Committer and PMC Member, will present, “In-Memory Computing Essentials for Java Architects and Developers”. The session will introduce software engineers and architects to the fundamental capabilities of distributed, in-memory systems and provide guidance on how to tap into a cluster’s resources.
• 
  I
  
  
  n-Memory Computing Summit
  
  
  2020 Virtual Worldwide Conference
  
  –
  On Demand
  – The In-Memory Computing Summit is the only industry-wide event focusing on the full range of in-memory computing technologies and solutions. Nearly 1,100 people representing 581 organizations from 53 countries registered for the late October conference to hear speakers from Dell, IBM, Intel, M&T Bank, MemVerge, Oracle, Target, ScaleOut Software, GridGain and more discuss the latest in-memory computing technologies and best practices. All conference keynote and breakout session video recordings are available on-demand.

About GridGain Systems

GridGain Systems is revolutionizing real-time data access and processing by offering an in-memory computing platform built on Apache^® Ignite^®. Common use cases for the GridGain platform include application acceleration and as a digital integration hub for real-time data access across data sources and applications. GridGain solutions are used by global enterprises in financial services, software, e-commerce, retail, online business services, healthcare, telecom, transportation and other major sectors, with a client list that includes ING, Raymond James, American Express, Société Générale, Finastra, UPS, Hewlett Packard Enterprise, Microsoft, RingCentral, American Airlines, Agilent, and UnitedHealthcareING, Raymond James, American Express, Société Générale, Finastra, IHS Markit, ServiceNow, Marketo, RingCentral, American Airlines, Agilent, and UnitedHealthcare. GridGain delivers unprecedented speed, massive scalability, and real-time data access for both legacy and greenfield applications. Deployed on a distributed cluster of commodity servers, GridGain software can reside between the application and data layers (RDBMS, NoSQL and Apache^® Hadoop^®), requiring no rip-and-replace of the existing databases, or it can be deployed as an in-memory database. For more information, visit gridgain.com.

CONTACT:

Terry Erisman
GridGain Systems
[email protected]
(650) 241-2281

GridGain is a trademark or registered trademark of GridGain Systems, Inc. Apache, Apache Hadoop, Hadoop, Apache Ignite, Ignite, Apache Kafka, Kafka, Apache Spark, and Spark are trademarks of The Apache Software Foundation. All other product and company names herein may be trademarks of their registered owners.

NEW HAVEN, Conn., Nov. 30, 2020 (GLOBE NEWSWIRE) — Kleo Pharmaceuticals, Inc., a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, announced that it will present data on KPMW135, a novel CD3 x CD20 bispecific molecule, created by chemically conjugating a CD3- binder directly to rituximab (Rituxan®) using its multi-targeted antibody therapy enhancer (MATE) platform. Data will be presented at the upcoming 62^nd American Society for Hematology (ASH) annual meeting, being held in a virtual format December 5- 8, 2020.

Details of the electronic presentation are as follows:

Title: KPMW135, a Biosuperior CD3 Bispecific Version of Rituximab Created by a Novel Chemical Conjugation Technology Demonstrates Increased Anti-Tumor Activity by Adding T Cell-Mediated Cytotoxicity Activity to the Existing Mechanisms of Rituximab
Number: 3009
Presenter: Christian Vidal, PhD
Program: Oral and Poster Abstracts
Session: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Poster III
Time and Location: Monday, December 7, 2020: 7:00 a.m. – 3 p.m. PST
Poster Hall (Virtual Meeting)

Kleo’s MATE platform enables site-directed chemical conjugation with off-the-shelf therapeutic antibodies to rapidly add or improve functionality to existing therapies. By MATE-ing a CD3 binder to rituximab, an anti-CD20 therapeutic monoclonal antibody used to treat B-cell lymphomas and lymphocytic leukemias, Kleo is able to retain rituximab’s existing mechanisms of action while adding potent and specific activation of T cells to destroy the tumor. In addition to oncology applications, the MATE platform is also being used to develop Kleo’s COVID-19 hyperimmune globulin mimic (HGM) therapy.

About Kleo Pharmaceuticals, Inc.

Kleo Pharmaceuticals is a targeted immunotherapy company that develops fully synthetic bispecific therapies to redirect, enhance or replace antibodies. The company was founded on the groundbreaking research of its scientific founder Dr. David Spiegel at Yale University. Kleo’s synthetic immunotherapy platform uses two chemistry-based approaches – antibody-redirecting molecule (ARM) and multi-targeted antibody therapy enhancer (MATE) – that help redirect and stimulate key components of the immune system to eradicate cancer cells and virulent pathogens. Compared to biologic therapies, Kleo’s compounds are smaller and more versatile, allowing for better tumor/tissue penetration, non-immunogenic for improved safety and higher dose levels, more efficient to produce and potentially orally bioavailable. They can be optimized against specified biological targets or combined with existing cell- or antibody-based therapies. Kleo investors include Biohaven Pharmaceutical Holding Company (NYSE:BHVN) and PeptiDream Inc. (Nikkei:PPTDF). For more information, visit www.kleopharmaceuticals.com.

CONTACT INFORMATION
LifeSci Advisors (Investors)
Irina Koffler
646-970-4681
[email protected]

Susan Kinkead (Media)
415-509-3610
[email protected]

ATLANTA, Nov. 30, 2020 (GLOBE NEWSWIRE) — Select Interior Concepts, Inc. (NASDAQ: SIC), a premier installer and nationwide distributor of interior building products, today announced that Bill Varner, CEO, and Nadeem Moiz, COO and CFO, will participate in the Truist 2020 Industrials and Services Summit on Tuesday, December 8, 2020.

SIC will meet with institutional investors at the conference, which is being held virtually. The Company’s investor presentation will be available in the “Investor Relations” section of the Company’s website at https://ir.selectinteriorconcepts.com.

About Select Interior Concepts

Select Interior Concepts is a premier installer and nationwide distributor of interior building products with leading market positions in highly attractive markets. Headquartered in Atlanta, Georgia, Select Interior Concepts is listed on the NASDAQ. The Residential Design Services segment provides integrated design, sourcing and installation solutions to customers, in the selection of a broad array of interior products and finishes, including flooring, cabinets, countertops, window treatments, and related interior items. The Architectural Surfaces Group segment distributes natural and engineered stone through a national network of distribution centers and showrooms under proprietary brand names such as Metroquartz and PentalQuartz. For more information, visit: www.selectinteriorconcepts.com.

CONTACT
:

Investor Relations:

Tully Brown
(470) 548-7370
[email protected] 

NEW HARTFORD, N.Y., Nov. 30, 2020 (GLOBE NEWSWIRE) — Printing & Graphics Association Mid Atlantic (PGAMA) announced today it has entered into a strategic partnership with MetLife, through its insurance consultant Gilroy Kernan & Gilroy, to provide its members with a co-branded Auto and Homeowners program designed specifically for print and graphic arts organizations.

“The mission of PGAMA has always been to provide world class programs and services to its members. Our main goal is to help our members prosper – especially during challenging economic times. During the unprecedented event of COVID-19 and the challenges it has created, many business and individuals seek relief from the effects of this disruptive pandemic as well as the many financial stresses it has created. The PGAMA/MetLife partnership was formed to address some of those financial stresses and to help our members overcome some of the many hurdles that our members and their employees now face.” Jay Goldscher– President, PGAMA

To learn more about details of the program, PGAMA and MetLife will be holding an informative webinar event on Tuesday, January 19th from 10:00 am – 10:30 am EST. Please contact Jay Goldscher, President of PGAMA at 410-319-0900 or via email [email protected] for more information and a link to the event.

About Gilroy Kernan & Gilroy, Inc.

Founded in 1904, Gilroy Kernan & Gilroy (gkgrisk.com) is one of Central New York States oldest and largest independent insurance agencies. Blending innovative insurance solutions with leading-edge strategies, GKG helps individuals and businesses of all types and sizes manage risk. The firm is headquartered at 210 Clinton Road in New Hartford, New York from which it serves clients around the nation and globe. GKG employs a professional staff of over 50 and represents more than 80 insurance carriers. If you would like more information about this topic, please contact Andrew Biernat or email at [email protected].

About
PGAMA

The Printing & Graphics Association Mid Atlantic https://pgama.com is the only regional trade association for the printing industry serving Maryland, Virginia and Washington, D.C. and is an affiliate of PRINTING United Alliance, the largest association dedicated to the printing and graphic industry in North America The mission of the PGAMA is to provide business relationships, expertise and education that ensure the strength and profitability of its member companies in the graphics, print and digital communications industries.

Contact		Andrew Biernat
Telephone		315.624.7819
Email		[email protected]
Website		www.gkgrisk.com

 

NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on Wednesday, December 2, 2020 at 9:15am ET.

The live and archived webcast can be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.

About Intra-Cellular Therapies

Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit www.intracellulartherapies.com.

CONTACT:

Intra-Cellular Therapies, Inc.
Juan Sanchez, M.D.
Vice President, Corporate Communications and Investor Relations
646-440-9333

Burns McClellan, Inc.
Lisa Burns
[email protected]
212-213-0006

TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) — CCL Industries Inc. (TSX:CCL.A) (TSX:CCL.B), a world leader in specialty label, security and packaging solutions for global corporations, government institutions, small businesses and consumers, announced today the closing of the acquisition of Super Enterprises Printing (Malaysia) Sdn. Bhd. (“SEP”), based in Kuala Lumpur, Malaysia. The company now trades as “CCL Design” with immediate effect.

Forward-looking Statements

This press release contains forward-looking information and forward-looking statements, as defined under applicable securities laws, (hereinafter collectively referred to as “forward-looking statements”) that involve a number of risks and uncertainties. Forward-looking statements include all statements that are predictive in nature or depend on future events or conditions. Forward looking statements are typically identified by the words “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans” or similar expressions. Statements regarding the operations, business, financial condition, priorities, ongoing objectives, strategies and outlook of the Company, other than statements of historical fact, are forward-looking statements.  

Forward-looking statements are not guarantees of future performance. They involve known and unknown risks and uncertainties relating to future events and conditions including, but not limited to, the impact  of the outbreak of the novel coronavirus known as COVID-19; instability of the world economy and capital markets; the impact of competition; consumer confidence and spending preferences; general economic and geopolitical conditions; currency exchange rates; interest rates and credit availability; technological changes; changes in government regulations; risks associated with operating and product hazards; and the Company’s ability to attract and retain qualified employees. Do not unduly rely on forward-looking statements as the Company’s actual results could differ materially from those anticipated in these forward-looking statements.

Forward-looking statements are also based on a number of assumptions, which may prove to be incorrect, including, but not limited to, assumptions about the following: consumer spending; improved customer demand for the Company’s products; continued historical growth trends, market growth in specific sectors and entering into new markets; the Company’s ability to provide a wide range of products to multinational customers on a global basis; the benefits of the Company’s focused strategies and operational approach; the achievement of the Company’s plans for improved efficiency and lower costs, including stable aluminum and resin costs; the availability of cash and credit; fluctuations of currency exchange rates and the Company’s continued relations with its customers. Should one or more risks come to fruition or should any assumption prove incorrect, then actual results could vary materially from those expressed or implied in the forward looking statements. Further details on key risks can be found in Section 4: “Risks and Uncertainties” of the 2019 Annual MD&A and and CCL’s Interim quarterly report for the period ended September 30, 2020.

For more information on CCL, visit – www.cclind.com or contact:

Sean Washchuk	Senior Vice President	416-756-8526
	and Chief Financial Officer

CCL Industries Inc. employs approximately 21,700 people operating 188 production facilities in 42 countries with corporate offices in Toronto, Canada, and Framingham, Massachusetts. CCL is the world’s largest converter of pressure sensitive and specialty extruded film materials for a wide range of decorative, instructional, functional and security applications for government institutions and large global customers in the consumer packaging, healthcare & chemicals, consumer electronic device and automotive markets. Extruded & laminated plastic tubes, aluminum aerosols & specialty bottles, folded instructional leaflets, precision decorated & die cut components, electronic displays, polymer banknote substrate and other complementary products and services are sold in parallel to specific end-use markets. Avery is the world’s largest supplier of labels, specialty converted media and software solutions for short-run digital printing applications for businesses and consumers available alongside complementary products sold through distributors, mass market stores and e-commerce retailers. Checkpoint is a leading developer of RF and RFID based technology systems for loss prevention and inventory management applications, including labeling and tagging solutions, for the retail and apparel industries worldwide. Innovia is a leading global producer of specialty, high performance, multi-layer, surface engineered films for label, packaging and security applications. The Company is partly backward integrated into materials science with capabilities in polymer extrusion, adhesive development, coating & lamination, surface engineering and metallurgy; deployed as needed across the four business segments.

VANCOUVER, British Columbia, Nov. 30, 2020 (GLOBE NEWSWIRE) — RevoluGROUP Canada Inc. (TSX-V: REVO), (Frankfurt:IJA2) (the “Company”) is pleased to announce that it has today incorporated into RevoluSEND sixty-eight extra countries and territories. Leveraging the PSD2 banking license and passporting approval, RevoluSEND now permits instant in-app remittance and bank transfers to an impressive group of additional countries.

SEPA
& IBAN
Added to
RevoluSEND

Further to the news release dated 24^th November 2020, the Company has completed the integration of 68 additional countries and territories into the RevoluSEND remittance vertical ahead of schedule. RevoluPAY app users may now send via RevoluSEND instant in-app transfers to proprietary or third-party bank accounts in: Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Great Britain, Greece, Greenland, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Albania, Azerbaijan, East Timor, El Salvador, Georgia, Israel, Kazakhstan, Kosovo, Kuwait, Macedonia, Montenegro, Palestine, São Tomé & Príncipe, Saudi Arabia, Andorra, Bahrain, Belarus, Bosnia & Herzegovina, British Virgin Islands, Cyprus, Gibraltar, Iraq, Jordan, Lebanon, Luxembourg, Malta, Rep. Mauritius, Mauritius Islands, Moldova, Monaco, Pakistan, Qatar, Saint Lucia, San Marino, Serbia, Seychelles, Switzerland, Turkey, Tunisia, Ukraine, United Arab Emirates.

Additional
Direct Passporting Countries

Additional to BTS and Thunes, the Company has also reached an autonomous interbank passporting functionality enabling bank transfers from RevoluPAY via RevoluSEND to Brazil, Costa Rica, Dominican Republic, Faroe Islands, and Guatemala. Since passporting countries are directly processed, no third-party delivery commissions are payable.

Open Banking Path Emerging

The Neobanking functionality of RevoluPAY is evolving into a one-stop banking app to challenge conventional bank accounts with proprietary mobile app-based technology. Today’s step enables users to instantly transmit payments from RevoluPAY to an impressive swathe of countries expected to exceed 130 in total by year’s end. As proved, RevoluSEND realizes such transactions at a fraction of the cost imposed by conventional banks or remittance entities. Future projected enhancements focus upon multicurrency, supporting in-app on-the-fly switchable currency accounts initially in CA$, USD, Euro, and GBP. Enabling RevoluPAY users to deposit a specific currency and transact directly in that currency is the next short-term corporate goal.

Exercise of I
ncentive
S
hare
O
ptions

CEO Steve Marshall has exercised an initial tranche of 500,000 of the incentive share options announced on 26^th June 2020 for a total of 120,000 $CA.

Links Used in This News Release

RevoluSEND https://revolusend.com/
RevoluPAY Passporting https://shortly.cc/2AbXI
PSD2 License https://shortly.cc/KAaNM
Ukraine Remittances https://shortly.cc/odfxA
Romania Remittances https://shortly.cc/3nVNA
Poland Remittances https://shortly.cc/Oo0OA
Serbia Remittances https://shortly.cc/cPOw0
European Remittance Study https://shortly.cc/8tGgT

A
bout RevoluPAY®

The Company’s flagship technology is RevoluPAY®, the Apple and Android multinational payment app. Built entirely in-house, RevoluPAY features proprietary, sector-specific technology of which the resulting source code is the property of the Company. RevoluPAY built-in features include Remittance Payments, Retail and Hospitality payments, Real Estate Payments, pay-as-you-go phone top-ups, Gift Cards & Online Credits, Utility Bill payments, Leisure payments, Travel Payments, etc. RevoluPAY is powered by blockchain protocols and is squarely aimed at the worldwide multi-billion dollar leisure sector and, + $595 billion family remittance market. RevoluPAY® is operated by the European wholly-owned subsidiary RevoluPAY S.L located in Barcelona. RevoluPAY S.L is the self-licensed European PSD2 payment institution 6900 under the auspices of E.U. Directive 2015/2366 and EU Passporting. RevoluGROUP Canada Inc. controls five wholly-owned subsidiaries on four continents.

About
RevoluGROUP Canada Inc.
:

RevoluGROUP Canada Inc. is a multi-asset, multidivisional publicly traded Canadian Company deploying advanced technologies in the; Banking, Mobile Apps, Money Remittance, Mobile Phone Top-Ups, EGaming, Healthcare Payments, Esports, Invoice factoring, Online Travel, Vacation Resort, Blockchain Systems, and Fintech app sectors. Click here to read more.

For further information on RevoluGROUP Canada Inc. (TSX-V: REVO), visit the Company’s website at www.RevoluGROUP.com. The Company has approximately 166,414,015 shares issued and outstanding.

RevoluGROUP Canada
,
Inc.

“
Steve Marshall
“

______________________
STEVE MARSHALL
CEO

For further information, contact:
RevoluGROUP Canada Inc.
Telephone: (604) 332 5355
Facsimile: (604) 687 3119
Email: [email protected]

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This release includes certain statements that may be deemed to be “forward-looking statements”. All statements in this release, other than statements of historical facts, that address events or developments that management of the Company expects, are forward-looking statements. Although management believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results or developments may differ materially from those in the forward-looking statements. The Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change. Factors that could cause actual results to differ materially from those in forward-looking statements, include market prices, exploration and development successes, continued availability of capital and financing, and general economic, market or business conditions. Please see the public filings of the Company at www.sedar.com for further information.

PHILADELPHIA, Nov. 30, 2020 (GLOBE NEWSWIRE) — Scout Bio, a biotechnology company revolutionizing pet medicine by delivering a pipeline of one-time gene therapies for major chronic pet health conditions, today announced that Mark Heffernan, Scout Bio’s Chief Executive Officer, will present on the “Blockbusters of 2024” panel at the upcoming Guggenheim Healthcare Talks Animal Health Veterinary Summit at 1:20 p.m. ET on Monday, December 7, 2020.

About Scout Bio

Scout Bio is a biotechnology company revolutionizing pet medicine by delivering a pipeline of one-time gene therapies for major chronic pet health conditions. Scout has an exclusive research and development collaboration with the University of Pennsylvania’s Gene Therapy Program, which has been a global leader in gene therapy research and development for nearly three decades. Scout’s therapeutics are designed to induce long-term expression of therapeutic proteins in pet patients using AAV vector technology. Scout Bio is ​a private company headquartered in Philadelphia, PA. For more information, please visit www.scoutbio.co.

Investor Contact:

Sarah McCabe
Stern Investor Relations, Inc.
212.362.1200
[email protected]

Media:
Fran Gaconnier
Scout Bio
214.417.4142
[email protected]